Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.50 |
| ▸ | HTR2A | P28223 | 3/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.50 |
| ▸ | HRH1 | P35367 | 3/20 | 0.50 |
| ▸ | DRD3 | P35462 | 3/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.50 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.50 |
| ▸ | DRD4 | P21917 | 2/20 | 0.50 |
| ▸ | DRD5 | P21918 | 2/20 | 0.50 |
| ▸ | HRH2 | P25021 | 2/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.50 |
| ▸ | HTR7 | P34969 | 2/20 | 0.50 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.50 |
| ▸ | HTR6 | P50406 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Difluanine SCHEMBL1813120 | 0.95 | SCN5A (0.59) | SCN5AKCNH2SLC6A3HTR2AADRA1A | |
| Difluanine SCHEMBL124263 | 0.94 | SCN5A (0.57) | SCN5AKCNH2SLC6A3HTR2AADRA1A | |
| Difluanine SCHEMBL28172554 | 0.94 | SCN5A (0.57) | SCN5AKCNH2SLC6A3HTR2AADRA1A | |
| SCHEMBL5077519 | 0.84 | HTR7 (0.67) | KCNH2SLC6A3HTR2AADRA1AHRH1 | |
| SCHEMBL7751410 | 0.83 | SLC6A3 (0.47) | SCN5AKCNH2SLC6A3HTR2AADRA1A | |
| Hydrochloric Acid SCHEMBL7543312 | 0.83 | MEN1 (0.48) | SCN5AKCNH2SLC6A3HTR2AADRA1A | |
| SCHEMBL8616378 | 0.80 | CYP3A4 (0.51) | SCN5AKCNH2SLC6A3HTR2AADRA1A | |
| SCHEMBL8615736 | 0.80 | CYP3A4 (0.51) | SCN5AKCNH2SLC6A3HTR2AADRA1A | |
| SCHEMBL4760958 | 0.80 | CYP3A4 (0.51) | SCN5AKCNH2SLC6A3HTR2AADRA1A | |
| Hydrochloric Acid SCHEMBL8867248 | 0.79 | MEN1 (0.52) | SCN5AKCNH2SLC6A3HTR2AADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1611116-A2 | CALCIUM CHANNEL INHIBITORS COMPRISING BENZHYDRIL SPACED FROM PIPERAZINE | Neuromed Technologies, Inc. (CA) | 2006-01-04 | — | — | EP | claimed |
| US-6943168-B2 | Calcium channel inhibitors comprising benzhydril spaced from piperazine | NEUROMED TECHNOLOGIES INC. (CA) | 2005-09-13 | — | — | US | claimed |
| US-20040266784-A1 | Calcium channel inhibitors comprising benzhydril spaced from piperazine | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-12-30 | — | — | US | claimed |
| WO-2004089922-A2 | CALCIUM CHANNEL INHIBITORS COMPRISING BENZHYDRIL SPACED FROM PIPERAZINE | NEUROMED TECHNOLOGIES, INC. (CA) | 2004-10-21 | — | — | WO | claimed |
| US-20040044004-A1 | Calcium channel inhibitors comprising benzhydril spaced from piperazine | NEUROMED TECHNOLOGIES, INC. | 2004-03-04 | — | — | US | claimed |
| US-20080300262-A1 | Combination Therapy for Relief of Pain | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-12-04 | — | — | US | disclosed |
| EP-1871372-A1 | COMBINATION THERAPY COMPRISING AN N-TYPE CALCIUM CHANNEL BLOCKER FOR THE ALLEVIATION OF PAIN | Neuromed Pharmaceuticals, Ltd. (CA) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006105670-A1 | COMBINATION THERAPY COMPRISING AN N-TYPE CALCIUM CHANNEL BLOCKER FOR THE ALLEVIATION OF PAIN | NEUROMED PHARMACEUTICALS LTD. (CA) | 2006-10-12 | — | — | WO | disclosed |
| WO-2004089922-A2 | CALCIUM CHANNEL INHIBITORS COMPRISING BENZHYDRIL SPACED FROM PIPERAZINE | NEUROMED TECHNOLOGIES, INC. (CA) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044004-A1 | Calcium channel inhibitors comprising benzhydril spaced from piperazine | CACNA1C, CACNA1F, CACNA1D | SCN5A 114/4885KCNH2 42/4885SLC6A3 1160/4885 |
| US-20040266784-A1 | Calcium channel inhibitors comprising benzhydril spaced from piperazine | CACNA1C, CACNA1F, CACNA1D | SCN5A 114/4885KCNH2 42/4885SLC6A3 1160/4885 |
| US-20080300262-A1 | Combination Therapy for Relief of Pain | CACNA1B, TRPV1, ORAI1 | SCN5A 97/4885KCNH2 109/4885SLC6A3 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.